Motrin and narcotic
Phase 3Small molecule
Motrin and narcotic is one of 12 small molecule programs targeting Pain, Postoperative. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Pain, Postoperative
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
Dolophine
HHikma Pharmaceuticals LLC
Approved
Tylenol
KKenvue Brands
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Marcaine
IInnocoll
Approved
Advil
KKenvue Brands
Approved
Acetominophen
Merck & Co.Phase 3
Tegileridine
XXin Chen
Phase 3
Liposomal Bupivacaine
TTLC Biopharmaceuticals, Inc.
Phase 2
Motrin and narcotic
CCape Fear Valley Health System
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Motrin and narcotic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCape Fear Valley Health System